Abstracts tagged "Disease Activity"

Abstract Number: 2472 • 2018 ACR/ARHP Annual Meeting
The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis
Maria Rydholm^1,2, Ingegerd Wikström^1,2, Sofia Hagel³, Lennart Jacobsson⁴ and Carl Turesson^1,2, ¹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Although patients with early rheumatoid arthritis (RA) have substantially reduced grip strength compared to the general population, some improvement over time has been demonstrated…
Abstract Number: 2722 • 2018 ACR/ARHP Annual Meeting
Incidence and Predictors of Severe Infections in ANCA Associated Vasculitis in a Population-Based Cohort – Preliminary Results
Jens Rathmann¹, David Jayne², Goran Jönsson³, Mårten Segelmark⁴, Jan-Åke Nilsson⁵ and Aladdin Mohammad², ¹Rheumatology, Skanes University Hospital, Lund, Lund, Sweden, ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Clinical Sciences, Nephrology, Lund University, Lund, Sweden, ⁵Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
Background/Purpose: To determine the incidence rates, predictors and outcome of severe infections in ANCA associated vasculitis (AAV). Methods: We conducted a population-based cohort study in…
Abstract Number: 2985 • 2018 ACR/ARHP Annual Meeting
Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies
Vibeke Norvang^1,2, Gina Hetland Brinkmann^1,3, Joseph Sexton¹, Anna-Birgitte Aga¹, Siri Lillegraven¹, Till Uhlig^1,2, Tore Kvien^1,2, Maria Dahl Mjaavatten¹ and Espen A. Haavardsholm^1,2, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²University of Oslo, Oslo, Norway, ³Dept. of Rheumatology, Østfold Hospital, Grålum, Norway
Background/Purpose: Treat-to-target (T2T) has become a key element in the management of rheumatoid arthritis (RA). Several different measures exist to define the preferred treatment target…
Abstract Number: 327 • 2018 ACR/ARHP Annual Meeting
The Patient Global Assessment and Common Composite Disease Activity Measures Vary Minimally When Patients Reflect on Their Arthritis or Their Global Health: Results from the Canadian Early Arthritis Cohort Study
Vivian P. Bykerk¹, Orit Schieir², Marie-France Valois³, Edward C. Keystone⁴, Gilles Boire⁵, Janet E. Pope⁶, Diane Tin⁷, Carol Hitchon⁸, Carter Thorne⁹, Susan J. Bartlett¹⁰ and Boulos Haraoui¹¹, ¹Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ²McGill University, Montreal, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto, Newmarket, ON, Canada, ¹⁰Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada
Background/Purpose: The patient global assessment (PtGA) is a core domain used in RA composite disease activity (CDA) measures for trials and treat-2-target paradigms. The PtGA…
Abstract Number: 632 • 2018 ACR/ARHP Annual Meeting
Interpretation of Symptoms Should Take into Account Gender in Psoriatic Arthritis: An Analysis of 451 Patients
Clémence Gorlier¹, Laure Gossec², Deborah Puyraimond-Zemmour¹, Laura C. Coates³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder¹⁵, Inna Gaydukova¹⁶, Ennio Lubrano¹⁷, Pascal Richette¹⁸, M. Elaine Husni¹⁹, Maarten de Wit²⁰, Josef S. Smolen²¹ and Ana-Maria Orbai²², ¹Sorbonne Université, PARIS, France, ²Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Rheumatology, Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁷Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁸Rheumatology, Université Paris Diderot, Paris, France, ¹⁹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²⁰Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Treatments targets in psoriatic arthritis (PsA) are remission (REM) or Low Disease Activity (LDA) which are usually defined based on objective disease activity but…
Abstract Number: 1458 • 2018 ACR/ARHP Annual Meeting
Impact of the Joint Presence of Erosions and ACPA on Rheumatoid Arthritis Disease Activity over Time: Results from the Meteor Registry
Sytske Anne Bergstra¹, Maura Couto², Nimmisha Govind³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, Elizabeth Murphy⁶, Tom W.J. Huizinga¹ and Cornelia F. Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²Hospital Sao Teotónio, Viseu, Portugal, Viseu, Portugal, ³University of the Witwatersrand, Johannesburg, South Africa, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶University Hospital Wishaw, Scotland, Wishaw, United Kingdom
Background/Purpose: Despite efforts to predict treatment response, treatment of rheumatoid arthritis (RA) patients remains mostly a case of trial and error. Previous research, mostly in…
Abstract Number: 1665 • 2018 ACR/ARHP Annual Meeting
Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression
Daniel Toro¹, Jordi Martorell-Marugán², Daniel Goldman³, Michelle Petri⁴, Pedro Carmona Sanz⁵ and Marta Alarcón-Riquelme^6,7, ¹Bioinformatics and Medical Genomics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Ganada, Spain, ²Bioinformatics Unit, Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ⁶Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain
Background/Purpose: The highly heterogeneous clinical presentation of lupus is characterized by the unpredictable appearance of flares of disease activity and important organ damage. Attempts to…
Abstract Number: 1923 • 2018 ACR/ARHP Annual Meeting
Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Elena Nikiphorou¹, Sam Norton², Adam Young³, Lewis Carpenter², Josh Dixey⁴, David Walsh⁵ and Patrick Kiely⁶, ¹Academic Rheumatology, Department of Inflammation Biology, King's College London, London, Great Britain, ²Academic Rheumatology, King's College London, London, United Kingdom, ³University of Hertfordshire, Hertford, United Kingdom, ⁴Rheumatology, The Royal Wolverhampton, Wolverhampton, United Kingdom, ⁵Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, ⁶Rheumatology Dept, St Georges Hospital, London, Great Britain
Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough? Background/Purpose: It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA)…
Abstract Number: 2484 • 2018 ACR/ARHP Annual Meeting
Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis
Ayako Kubota¹, Toru Suguro¹, Arata Nakajima², Masato Sonobe³ and Kazuaki Tsuchiya¹, ¹Toho University Omori Medical Center, Tokyo, Japan, ²Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, ³Toho University Sakura Medical Center, Chiba, Japan
Background/Purpose: Multiple studies addressing the effects of biologics on the synovial tissue in rheumatoid arthritis (RA) patients have been reported. There are, however, few studies…
Abstract Number: 2785 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 1-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
Ronald van Vollenhoven¹, Bevra H Hahn², George C Tsokos³, Carrie Wagner⁴, Peter Lipsky⁵, Benjamin Hsu⁴, Marc Chevrier⁴, Robert Gordon⁴, Kim Hung Lo⁴, Manon Triebel⁶, Kaiyin Fei⁴ and Shawn Rose⁴, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²University of California, Los Angeles, CA, ³Beth Israel Hospital, Boston, MA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ⁶Janssen Biologics Europe, Leiden, Netherlands
Background/Purpose: Both the IL-12 and IL-23 pathways have been linked to SLE pathogenesis. The anti-IL-12/23 p40 monoclonal antibody ustekinumab (UST), which is approved for psoriasis,…
Abstract Number: 2986 • 2018 ACR/ARHP Annual Meeting
The Impact of Exercise and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study
Nancy A. Shadick¹, Christine K Iannaccone², Patricia Katz³, Gabriela L. Maica⁴, Jonathan Coblyn⁵, Michael E Weinblatt⁶ and Jing Cui⁷, ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³University of California San Francisco, San Francisco, CA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Modifiable lifestyle factors such as inactivity and obesity contribute to cognitive decline in the general population, but little is known about how these factors…
Abstract Number: 328 • 2018 ACR/ARHP Annual Meeting
Implementation of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Documentation in Systemic Lupus Erythematosus (SLE) Patients at an Academic Medical Center
Sarah H. Chung¹, Hsin-Hsuan Juo², Jenna Thomason¹ and Alison Bays³, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²rheumatology, University of Washington, seattle, WA, ³Rheumatology, University of Washington, Seattle, WA
Background/Purpose: The 2008 European League Against Rheumatism (EULAR) Task Force on SLE management encourages the use of at least one of the SLE disease indices…
Abstract Number: 636 • 2018 ACR/ARHP Annual Meeting
Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors
Laure Gossec^1,2, Paul Bergmans³, Kurt de Vlam⁴, Elisa Gremese⁵, Beatriz E. Joven⁶, Tatiana Korotaeva⁷, Michael Nurmohamed^8,9, Petros Sfikakis¹⁰, Stefan Siebert¹¹, Pavel Smirnov¹², Elke Theander¹³ and Josef S. Smolen¹⁴, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Sorbonne Université, Paris, France, ³Biometrics, Janssen-Cilag B.V., Breda, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, ⁸Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ¹⁰Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ¹¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Cardiff, United Kingdom, ¹²Biometrics, Janssen-Cilag B.V., Moscow, Russian Federation, ¹³Biometrics, Janssen-Cilag B.V., Solna, Sweden, ¹⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: The link between treatment recommendations for PsA (to aim for a state of remission or low disease activity (LDA))1,2 and patient-important outcomes has been…
Abstract Number: 1460 • 2018 ACR/ARHP Annual Meeting
Plasma Mir-146a-5p Associates with Beneficial Body Composition and Plasma Metabolic Profiles in Rheumatoid Arthritis
Brian J. Andonian¹, Ching-Heng Chou², Virginia B. Kraus², William E. Kraus³ and Kim M. Huffman⁴, ¹Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ²Duke Molecular Physiology Institute, Duke University, Durham, NC, ³Medicine, Duke University, Durham, NC, ⁴School of Medicine, Division of Rheumatology, Immunology and Molecular Physiology and Durham VA Medical Center, Duke University, Durham, NC
Background/Purpose: In rheumatoid arthritis (RA), sarcopenic obesity is associated with significant cardiometabolic disease and mortality. Biomarkers of disease activity in RA and obesity are complicated…
Abstract Number: 1674 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker Validation in a Large European Spanish Lupus Registry Cohort
Meenakshi Jolly¹, Desiree R Azizoddin², Iñigo Rúa-Figueroa³, Hervé Devilliers⁴, Raúl Menor Almagro⁵, Francisco Javier López Longo⁶, Juan Gabriel Ovalles-Bonilla⁷, Alejandro Olivé-Marqués⁸, Paula Rubio-Muñoz⁸, María Galindo⁹, Antonio Fernandez-Nebro¹⁰, Jaime Calvo-Alen¹¹, Rosario García-Vicuña¹², Eva Tomero¹³, Esther Uriarte Isacelaya¹⁴, Angela Pecondon-Español¹⁵, Ricardo Blanco¹⁶, Mercedes Freire¹⁷, Marian Gantes¹⁸, Monica Ibanez Barcelo¹⁹, Carlos Alberto Montilla-Morales²⁰, José Rosas²¹, Jesús García-Villanueva²², Paloma Vela²³, Esther Ruiz Lucea²⁴, Francisco Toyos²⁵, José Hernández Beiraín²⁶, Elvira Diez Alvarez²⁷, María Gema Bonilla Hernán²⁸, Francisco Javier Narváez²⁹, José Andréu-Sánchez³⁰, Mireia Moreno-Martínez-Losa³¹, Ana Sánchez Atrio³², Maria Loreto Horcada³³, Tatiana Cobo-Ibáñez³⁴, Carlos Marras Fernandez-Cid³⁵, Tomas Ramón Vazquez Rodriguez³⁶, Eva Salgado-Pérez³⁷, Vicente Torrente³⁸, Juan Alegre-Sancho³⁹, Coral Mouriño-Rodriguez⁴⁰, Joel A. Block⁴¹ and JM Pego-Reigosa⁴², ¹Rush University Medical Center, Chicago, IL, ²Department of Anesthesiology, Stanford University School of Medicine, Palo Alto, CA, ³Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Rheumatology, Hospital de Jerez de la Frontera, Jerez, Spain, ⁶Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁸Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ¹⁰UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga Departamento de Medicina y Dermatología, Universidad de Málaga, MÁLAGA, Spain, ¹¹Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ¹²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹³HOSPITAL DE LA PRINCESA, spain, Spain, ¹⁴Rheumatology, Hospital Universitario de Donosti, San Sebastian, Spain, ¹⁵Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ¹⁶Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁷Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁸Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ¹⁹H. Son Llatzer, Palma de Mallorca, Spain, ²⁰Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ²¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²²HOSPITAL RAMÓN Y CAJAL, Madrid, Spain, ²³Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ²⁴Rheumatology, Hospital de Basurto, Bilbao, Spain, ²⁵Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ²⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²⁷Complejo Asistencial Universitario de León, León, Spain, ²⁸Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ²⁹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ³⁰HOSPITAL PUERTA DE HIERRO, Madrid, Spain, ³¹HOSPITAL PARC TAULÍ, Barcelona, Spain, ³²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ³³Rheumatology, Hospital de Navarra, Pamplona, Spain, ³⁴Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³⁵Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁷COMPLEJO HOSPITALARIO DE OURENSE, Ourense, Spain, ³⁸Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ³⁹HOSPITAL DR. PESET, València, Spain, ⁴⁰Rheumatology, Rheumatology Section, Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain, Vigo, Spain, ⁴¹Rheumatology, Rush University Medical Center, Chicago, IL, ⁴²Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Background/Purpose: Lupus Impact Tracker (LIT) is a ten item unidimensional patient reported outcome tool developed from and for patients with systemic lupus erythematosus (SLE). It…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].